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centers may help to provide conclusive evidence.312
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Alemtuzumab, ﬂudarabine, and melphalan reduced intensity
conditioning regimens are increasingly used for the he-
matopoietic cell transplantation of pediatric and young adult
patients with non-malignant diseases. Data regarding large
patient groups are limited. We retrospectively analyzed the
outcomes of 206 patients with primary immunodeﬁciencies,
metabolic diseases, and non-fanconi anemia marrow failure
disorders who underwent 210 RIC HCT procedures at Cin-
cinnati Children’s Hospital. Ninety-seven percent of patients
engrafted. Mixed donor and recipient chimerism developed
in 46% of patients. The risk was highest in patients who
received proximal or higher dose/kg alemtuzumab schedules
(all HR>2, all p<0.05) or cord blood grafts (HR 3.122, CI
1.236-7.888, p¼ 0.016). Patients with marrow failure were
protected against mixed chimerism (HR 0.208, CI 0.061-
0.709, p¼0.012). The overall cumulative incidences of grades
II-IV and III-IV acute GHVDwere 25% (CI 20-32%) and 18% (CI
14%-25%). Five percent of patients required re-trans-
plantation. One-year survival without re-transplantationwas
75% (CI 69-81%). Only 2 deaths were related to acute toxic-
ities; themajority were related to infections. Age, HLAmatch,
and grades III-IV acute GVHD impacted survival. Despite the
high incidence of mixed chimerism, alemtuzumab, ﬂudar-
abine, and melphalan RIC HCT offers minimal life-threat-
ening acute toxicities and good outcomes for many patients.313
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reduced intensity conditioning (RIC) regimens are increas-
ingly used for pediatric patients with non-malignant dis-
eases. We have previously reported that the incidences of
acute graft versus host disease (GVHD) andmixed chimerism
are both inﬂuenced by the timing and dose of alemtuzumab.
We speculated that these effects were due to variations in
peri-transplant levels of alemtuzumab and resultant differ-
ences in extent of graft T cell depletion.
Hypothesis: We hypothesized that low or absent levels of
alemtuzumab would result in elevated risk for acute GVHD
but low risk of mixed chimerism, and that high levels of
alemtuzumab would result in low risk of acute GVHD but
increased risk of mixed chimerism.
Methods: We measured alemtuzumab levels on the day of
graft infusion +/- 3 days in 90 patients who received an
alemtuzumab, ﬂudarabine, and melphalan RIC regimen. We
created cumulative incidence curves to compare the in-
cidences of acute GVHD grades II-IV and mixed chimerism in
patients with alemtuzumab levels of 0.1mg/mL or less versus
0.2mg/mL or greater. We used cause-speciﬁc Cox hazard
regression to model the risks of acute grades II-IV GVHD or
mixed chimerism (deﬁned as whole blood donor chimerism
of less than 95% on two or more consecutive occasions)
taking into account the covariates of age, diagnosis, HLA
Match, graft source, and alemtuzumab level (mg/mL,
continuous variable). All computations were done using R
(The R Foundation for Statistical Computing, Vienna,
Austria). Final models were selected using stepwise selec-
tion. Statistical signiﬁcance was considered for p<0.05.
Results: The cumulative incidence of acute GVHD grades II-
IV was 48% in patients with alemtuzumab levels of 0.1 mg/mL
or less, and 18% in patients with levels of 0.2mg/mL or greater
(p<0.001). The cumulative incidence of mixed chimerism
was 34% in patients with alemtuzumab levels of 0.1 mg/mL or
less, and 48% in patients with levels of 0.2mg/mL or greater
(p¼0.24). In multivariate analysis, we found that alemtuzu-
mab level was the only signiﬁcant factor associated with the
risks of acute grades II-IV GVHD and mixed chimerism.
Increasing levels of alemtuzumab decreased the risk of
grades II-IV acute GVHD (HR 0.495, CI 0.282-0.867, p¼0.014).
Conversely, increasing levels of alemtuzumab increased the
risk of mixed chimerism (HR 1.169, CI 1.033-1.324, p¼0.014).
Receipt of a cord blood graft also inﬂuenced the risk (HR
4.134, p¼0.068) but did not reach statistical signiﬁcance,
perhaps due to small sample size.
Conclusion: We conclude that peri-transplant levels of
alemtuzumab dictate the risks for acute GVHD and mixed
chimerism. Detailed pharmacokinetic studies are needed to
optimize and individualize alemtuzumab dosing for pediat-
ric patients in order to minimize these complications.314
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Background: Myeloablative conditioning regimens used for
hematopoietic stem cell transplant (HSCT) are known to
affect endocrine function, most commonly causing primary
Table 1
Patient characteristics
Characteristics Number or
Median(range)
Number of patients 27
Pre-HSCT nuclear GFR (mL/min/1.73m2)
 Patients with renal abnormalities (n¼12) 97 (55-131)
Mild Renal impairment (GFR<90) 4
Moderate Renal impairment (GFR<60) 2
 Patients without renal abnormalities (n¼15) 124 (71-199)
Mild Renal impairment (GFR<90) 2
Post-HSCT renal complications
 Acute kidney injury (doubling of creatinine) 12
 Mild Renal impairment (GFR<90mL/min) 14
 Moderate Renal impairment (GFR<60mL/min) 10
 Severe Renal impairment requiring temporary RRT 1
Attributable Causes for renal complications
(not mutually exclusive)
 Transplant associated thrombotic microangiopathy 9
 BK hemorrhagic cystitis 11
 Nephrotoxic medications 6
 Hepato-renal syndrome due to VOD 1
Early withdrawal of CSA due to renal impairment 11
Post-HSCT Renal Function
 Recovery to GFR>60mL/min at least
In patients with mild renal impairment post-HSCT 13/14
(GFR<90mL/min)
In patients with moderate renal impairment
post-HSCT
5/10
(GFR<60mL/min)
 Chronic Kidney Disease without dialysis
(GFR 35-40mL/min)
2
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regarding these late effects after newer reduced intensity
conditioning (RIC) regimens without irradiation. Our study
goal was to evaluate late endocrine effects after RIC HSCT in
pediatric and young adult patients.
Methods: An IRB approved retrospective chart review was
performed of 120 children and young adults at our center,
who received a single RIC without radiation for HSCT be-
tween 2004 and 2012 and survived at least 1 year. Analysis
was grouped by age (<2 years and 2 years), and diagnosis
(HLH/XLP, other immune disorders (PID), and metabolic or
genetic disorders). Steroid therapy was deﬁned as glucocor-
ticoids administered either before HSCT or beyond 2 months
following HSCT. Height for age z-score (HAZ) and BMI z-
scores (BMI-Z) were examined separately using linear mixed
effects models.
Results: Subjects age 2-17y with height (n¼103) and weight
(n¼120) data both prior to and at least 1 year following HSCT
were analysed for growth. Themean follow-upwas 3.2 years.
All groups displayed short stature before (HAZ ¼ -1.33) and
after HSCT (HAZ ¼ -1.35) (p¼0.66). After HSCT, younger
children with HLH/XLP grew better (HAZ ¼-3.36 vs -1.35, p¼
0.002), while older subjects had worsening (HAZ ¼-.61 vs
-.99, p¼ 0.004), although all remained short. Overall, subjects
receiving steroid therapy were shorter than untreated pa-
tients (p¼0.02). After HSCT, older subjects with HLH/XLP
became thinner (BMI-Z¼ 1.29 vs. 0.61, p¼0.003), and simi-
larly in metabolic or genetic disorders (BMI-Z¼ 0.56 vs. -0.77,
p<0.001). There was a trend toward increased BMI-Z among
younger children in these same groups. Thyroid function
testing was performed on 77 subjects following HSCT. Eleven
(14%) had evidence of primary hypothyroidism, 5 (7%) had
central hypothyroidism, and 2 (3%) had evidence of primary
hyperthyroidism. Of the 66 subjects with 25-OH vitamin D
levels, 46 (70%) were low (<30 ng/mL). Bone densitometry
by DXA scan was below -1 SD in 16 of 21 evaluable subjects
with an average Z-score of -1.8 SD (0.7 to -4.9 SD) at median
duration after HSCT of 2.2 years.
Conclusions: Despite using RIC, children and young adults
still have signiﬁcant late endocrine effects following trans-
plant. Algorithms for early detection of endocrine late effects
should be implemented for RIC transplant survivors. Further
research is required in order to compare post-transplant
endocrine effects after RIC to those after standard chemo-
therapy protocols.315
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Background: Renal and urological congenital abnormalities
in patients with FA raise concern for renal dysfunction and
may affect their eligibility to undergo HSCT or their post-
transplant course and outcome. Some of these patients (or
their physicians) may opt not to proceed with HSCT due to
concerns of adverse outcome. We describe renal anomalies
and associated dysfunction, and their impact on outcomes in
a cohort of patients with FA undergoing HSCT.
Methods: A retrospective chart review of 27 patients with FA
who underwent HSCT between March 2010 and May 2014.Results: 12 patients had structural renal/urological abnor-
malities at baseline. Median nuclear GFR for these patients
was 97 mL/min/1.73sq.m (range: 55-131) compared to 124
mL/min/1.73sq.m (range: 71-199) in those without renal
anomalies (p¼0.03). Additional patient characteristics and
results are shown in Table 1.
Post-HCT renal complications included acute kidney
injury and decreased renal function measured by Cystatin C
GFR. One patient required renal replacement therapy.
Medication doses were adjusted based on Cyst C GFR for all
patients.
The majority of patients (13/14) with renal impairment
pre-transplant recovered to GFR>60mL/min post-transplant.
2 patients with anomalies and pre-HCT GFR <60 mL/min/
1.73sq.m are long term survivors, albeit with modest chronic
kidney disease (CKD) but without the need for dialysis.
Conclusion: Patients with structural renal abnormalities had
lower but surprisingly clinically acceptable pre-HCT GFR.
Two patients with anomalies and pre-HCT GFR <60, are long
term survivors, showing that patients with renal anomalies/
marginal renal function can consider the option of HCT.
Routine weekly Cystatin C-GFR allows careful and individu-
alized medication dosing leading to improved outcomes.316
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